ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
企業コードNDRA
会社名ENDRA Life Sciences Inc
上場日Jun 28, 2017
最高経営責任者「CEO」Mr. Alexander Y. Tokman
従業員数21
証券種類Ordinary Share
決算期末Jun 28
本社所在地3600 Green Ct Ste 350
都市ANN ARBOR
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号48105-2440
電話番号17343350468
ウェブサイトhttps://www.endrainc.com/
企業コードNDRA
上場日Jun 28, 2017
最高経営責任者「CEO」Mr. Alexander Y. Tokman
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし